NCT01236586撤回1 期
A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- The primary outcomes of this study are self-reported fatigue, depression, and quality of life scores of patients before, at midpoint, and at completion of each cycle of their cancer treatment.
研究概览
简要总结
Background:
- The anti-cancer drug RO4929097 is being tested for its ability to block blood vessel growth to tumors and slow or stop the growth of cancer cells. However, it has been used in only a small number of adults and has not yet been tested in children. Researchers are interested in determining whether RO4929097 is a safe and effective treatment for tumors or leukemia that has not responded to standard treatment.
Objectives:
- To determine the safety and effectiveness of RO4929097 as a treatment for children and adolescents who have been diagnosed with certain kinds of cancer that have not responded to standard treatment.
Eligibility:
- Children, adolescents, and young adults between 1 and 21 years of age who have been diagnosed with solid, nervous system, or blood-based cancers that have not responded to standard treatment.
Design:
- Participants will be screened with a medical history, physical examination, blood and urine tests, and imaging studies. Some participants may also have a bone marrow biopsy to evaluate the state of their disease.
- Participants will be separated into three groups: One group will receive RO4929097 alone, and the other two will receive RO4929097 in combination with the immune-suppressing drug dexamethasone.
- RO4929097 will be given as tablets on one of two schedules: days 1 to 3 of every week (Schedule A) or days 1 to 5 of every week (Schedule B). The dosing schedule will be determined randomly. Every 4-week treatment period is one cycle, and participants may receive RO4929097 for up to 24 cycles.
- Participants will have frequent blood and urine tests and imaging studies to evaluate the progress of treatment, and will be asked to keep a diary to monitor any side effects.
详细描述
Background:
- Notch signaling is aberrantly activated in a variety of human tumors including solid tumors and hematological malignancies including T-cell leukemia (T-ALL) and pediatric cancers, such as osteosarcoma, gliomas, medulloblastomas, ependymoma, and hematological malignancies.
- One emerging strategy to inhibit Notch signaling is the use of gamma-secretase inhibitors (GSIs), which prevent Notch receptor activation cleavage.
- RO4929097 is an orally administered small molecule that is a potent and selective GSI, which has shown antitumor activity in preclinical studies.
Objectives:
- To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose, and associated toxicities of RO4929097 administered orally to children with relapsed/refractory solid tumors or lymphoma on 2 schedules: once daily orally on a 3 day on/4 day off weekly schedule (schedule A) and once daily for 5 consecutive days weekly schedule (schedule B).
- To determine the MTD and recommended Phase 2 dose, and associated toxicities of RO4929097 administered with dexamethasone.
- To characterize the pharmacokinetics of RO4929097 in children with refractory cancer.
- To preliminarily define the anti-tumor activity of RO4929097 in children with refractory solid tumors within the confines of a phase I study.
- To determine initial efficacy on the anti-tumor activity of RO4929097 when combined with dexamethasone in children with relapsed/refractory T-ALL.
- To study the effects of RO4929097 on components of the Notch signaling pathway in peripheral blood mononuclear cells and/or T-ALL blasts, to examine archival tumor samples for expression or amplification of target molecules, and to preliminarily assess changes after treatment using FDG PET imaging.
Eligibility:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ELIGIBILITY CRITERIA:
- •Patients greater than 12 months and less than or equal to 21 years of age with a diagnosis and histologic verification (except patients with intrinsic brain stem tumors, optic pathway gliomas) of measureable or evaluable relapsed or refractory disease. Current disease state must be one for which there is no known curative therapy, or therapy proven to prolong survival with an acceptable quality of life.
- •Subjects must be able to swallow tablets.
- •Patients who are pregnant, are known to be serologically positive for Hepatitis A, B, C, or have a history of liver disease, or have prolonged QTc are not eligible.
排除标准
- 未提供
结局指标
主要结局
The primary outcomes of this study are self-reported fatigue, depression, and quality of life scores of patients before, at midpoint, and at completion of each cycle of their cancer treatment.
次要结局
- Cytokine profile
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Infratentorial EpendymomaChildhood Supratentorial EpendymomaRecurrent Childhood Large Cell LymphomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaChildhood Atypical Teratoid/Rhabdoid TumorChildhood Choroid Plexus TumorPituitary Eosinophilic AdenomaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Spinal Cord NeoplasmRecurrent/Refractory Childhood Hodgkin LymphomaChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System TeratomaChildhood EpendymoblastomaChildhood Grade III MeningiomaChildhood MedulloepitheliomaChildhood Mixed GliomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Central Nervous System Embryonal TumorRecurrent Childhood PineoblastomaT-cell Large Granular Lymphocyte LeukemiaTSH Secreting AdenomaGonadotroph AdenomaPituitary Basophilic AdenomaPituitary Chromophobe AdenomaProlactin Secreting AdenomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Small Noncleaved Cell LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificChildhood Central Nervous System GerminomaChildhood Central Nervous System Yolk Sac TumorChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood OligodendrogliomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood MedulloblastomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Pituitary TumorT-cell Childhood Acute Lymphoblastic LeukemiaNCT01088763National Cancer Institute (NCI)129
撤回
2 期
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by SurgeryStage IV MelanomaStage IIIC MelanomaStage IIIB MelanomaNCT01216787National Cancer Institute (NCI)
已完成
2 期
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerNCT01175343National Cancer Institute (NCI)45
已完成
1 期
RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsStage III Colon CancerStage III Small Lymphocytic LymphomaStage IV Mycosis Fungoides/Sezary SyndromeRecurrent Adult Lymphoblastic LymphomaAIDS-related Diffuse Large Cell LymphomaAIDS-related Primary CNS LymphomaAIDS-related Small Noncleaved Cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Hodgkin LymphomaAnaplastic Large Cell LymphomaPost-transplant Lymphoproliferative DisorderStage III Grade 1 Follicular LymphomaStage IV Adult Diffuse Large Cell LymphomaAdult Grade III Lymphomatoid GranulomatosisAIDS-related Diffuse Small Cleaved Cell LymphomaAIDS-related Immunoblastic Large Cell LymphomaAIDS-related Peripheral/Systemic LymphomaHER2-negative Breast CancerPrimary Central Nervous System Non-Hodgkin LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Breast CancerRecurrent Colon CancerSplenic Marginal Zone LymphomaStage III Adult Diffuse Mixed Cell LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Hodgkin LymphomaStage IV Breast CancerStage IV Colon CancerAIDS-related Lymphoblastic LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Small Lymphocytic LymphomaSmall Intestine LymphomaStage III Adult Diffuse Large Cell LymphomaStage III Adult Hodgkin LymphomaStage III Adult Lymphoblastic LymphomaCutaneous B-cell Non-Hodgkin LymphomaHIV-associated Hodgkin LymphomaPrimary Central Nervous System Hodgkin LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone LymphomaStage III Adult Burkitt LymphomaStage IV Adult Diffuse Mixed Cell LymphomaStage IV Grade 3 Follicular LymphomaStage IV Mantle Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Rectal CancerStage III Adult Diffuse Small Cleaved Cell LymphomaStage III Grade 3 Follicular LymphomaStage III Marginal Zone LymphomaStage III Mycosis Fungoides/Sezary SyndromeStage III Rectal CancerStage IIIC Breast CancerStage IV Adult Diffuse Small Cleaved Cell LymphomaMale Breast CancerAdult Nasal Type Extranodal NK/T-cell LymphomaAIDS-related Diffuse Mixed Cell LymphomaAngioimmunoblastic T-cell LymphomaRecurrent Mantle Cell LymphomaStage III Adult Immunoblastic Large Cell LymphomaStage III Adult T-cell Leukemia/LymphomaStage III Cutaneous T-cell Non-Hodgkin LymphomaStage III Grade 2 Follicular LymphomaStage III Mantle Cell LymphomaStage IIIA Breast CancerStage IIIB Breast CancerStage IV Adult Immunoblastic Large Cell LymphomaStage IV Adult Lymphoblastic LymphomaStage IV Adult T-cell Leukemia/LymphomaStage IV Cutaneous T-cell Non-Hodgkin LymphomaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaWaldenström MacroglobulinemiaStage IV Marginal Zone LymphomaStage IV Rectal CancerStage IV Small Lymphocytic LymphomaUnspecified Adult Solid Tumor, Protocol SpecificNCT01158274National Cancer Institute (NCI)30
终止
1 期
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerMale Breast CarcinomaEstrogen Receptor PositiveHER2/Neu NegativeRecurrent Breast CarcinomaStage IV Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerNCT01149356National Cancer Institute (NCI)15